What is Cellectis SA (CLLS) stock price today?

Cellectis SA (CLLS) currently trades at $3.90 per share. The stock has a market capitalization of $391.30M and a P/E ratio of —x.

Is CLLS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Cellectis SA has a Smart Value Score of 16/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -0.67.

What is Cellectis SA's revenue and earnings?

Cellectis SA has trailing twelve-month (TTM) revenue of $79.59M with profit margins of -84.90%. Earnings per share (EPS) is $-0.67.

Is Cellectis SA financially healthy?

Cellectis SA's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -0.67 places it in the distress.

CLLS

Cellectis SA

NASDAQ: CLLS · HEALTHCARE · BIOTECHNOLOGY

$3.90

+4.56% today

Updated 2026-04-30

Market cap

$391.30M

P/E ratio

—

P/S ratio

4.92x

EPS (TTM)

$-0.67

Dividend yield

—

52W range

$1 – $5

Volume

0.0M

Market cap

$391.30M

P/E ratio

—

P/S ratio

4.92x

EPS (TTM)

$-0.67

Dividend yield

—

52W range

$1 – $5

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

4.5

Quality

2.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-0.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$7.25

+85.90%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy2 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.37x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -0.67 — distress zone

- Thin margins at -84.90%

- Negative free cash flow $-10.95M

- Revenue declining -19.50% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$19.17M	$755000.00	$41.51M	$73.17M	$79.59M
Net income	$-98.69M	$-101.06M	$-36.76M	$-67.80M	$-26.30M
EPS	—	—	—	—	$-0.67
Free cash flow	$-89.89M	$-25.82M	$19.52M	$-42.50M	$-10.95M
Profit margin	-514.78%	-13,385.30%	-88.57%	-92.66%	-84.90%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CLLS	$391.30M	16	5.3	2.0	5.0	4.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Cellectis SA trades at $3.90. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -0.67, it sits in the distress. TTM revenue stands at $79.59M. with profit margins at -84.90%.

Frequently asked questions

What is Cellectis SA's stock price?

Cellectis SA (CLLS) trades at $3.90.

Is Cellectis SA overvalued?

Smart Value Score 16/100 (Grade F, Strong Sell).

What is the price target of Cellectis SA (CLLS)?

The analyst target price is $7.25, representing +85.9% upside from the current price of $3.90.

What is Cellectis SA's revenue?

TTM revenue is $79.59M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-0.67 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.cellectis.com

Quick metrics

P/S ratio4.92x

ROE-65.30%

Beta2.71

50D MA$3.69

200D MA$3.61

Shares out0.07B

Float0.05B

Short ratio—

Avg volume0.0M

Performance

1 week-11.99%

1 month+26.30%

3 months-11.99%

YTD-19.63%

1 year—

3 years—

5 years—

Compare

CLLS vs LLY →CLLS vs JNJ →CLLS vs ABBV →Stock screener →